國家衛生研究院 NHRI:Item 3990099045/11441
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12500/13673 (91%)
造訪人次 : 2854575      線上人數 : 705
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11441


    題名: Size effect on tumor treatment with PEGylated liposomal drugs in a tumor-bearing mouse model
    作者: Lin, YY;Li, JJ;Weng, MC;Hwang, JJ;Tseng, YL;Lin, MH;Lin, WJ;Ting, G;Wang, HE
    貢獻者: National Institute of Cancer Research
    摘要: Objectives PEGylated liposomes are important drug carriers, which can passively target tumor by enhanced permeability and retention effect in neoplasm lesions. This study evaluated the influence of tumor size on the therapeutic efficacy of In-111 and/or vinorelbine (VNB)-encapsulated PEGylated liposomes in a C26/tk-luc colon carcinoma-bearing mouse model. Methods PEGylated liposomes (NanoX) and those encapsulated with VNB (NanoVNB) were labeled with In-111 to afford InNanoX or InVNBL. BALB/c mice bearing C26/tk-luc tumors (small, 58.4 ± 8.0 mm3; large, 102.4 ± 22.0 mm3) in the right dorsal flank were individually administered intravenously with NanoX, NanoVNB, InNanoX or InVNBL 3 times in 2 weeks. The therapeutic efficacy was evaluated by body weight loss, tumor growth inhibition and survival fraction. The scintigraphic imaging was also performed during the period of treatment. Results The radiochemical purity of InNanoX and InVNBL were both > 90%. Biodistribution studies showed high tumor uptake since 24 h post injection (p.i.) of InVNBL, especially in the small-tumor bearing mice. In both small-tumor and large-tumor mouse models, mice treated with InVNBL showed the best tumor growth inhibition rate and the highest survival rate compared with those treated with other drugs. All liposomal drugs showed better therapeutic efficacy in mice bearing small tumors than those bearing large tumors. InVNBL-SPECT imaging also revealed significant tumor targeting, especially in small-tumor bearing mice, during the period of treatment. Conclusions This study demonstrates that InVNBL is a potent antitumor agent especially in the small-tumor bearing mouse model. The results suggest that PEGylated liposomal drugs may be most valuable for the treatment initiated at the early stage of tumor’s growth or tumor metastases
    日期: 2011-05
    關聯: Journal of Nuclear Medicine. 2011 May;52(Suppl. 1):Meeting Abstract 1737.
    Link to: http://jnm.snmjournals.org/content/52/supplement_1/1737
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0161-5505&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000443798902219
    顯示於類別:[其他] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000443798902219.pdf57KbAdobe PDF255檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋